NASDAQ:ASMB
Assembly Biosciences Stock News
$13.41
+0.0800 (+0.600%)
At Close: Apr 19, 2024
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
08:00am, Wednesday, 09'th Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Friday, 07'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
01:00pm, Thursday, 06'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
08:00am, Thursday, 06'th Jan 2022
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)
03:00pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)
11:36am, Tuesday, 07'th Dec 2021
Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Assembly Biosciences (NASDAQ:ASMB) Stock Rating Upgraded by Zacks Investment Research
06:46am, Tuesday, 07'th Dec 2021 Dakota Financial News
Zacks Investment Research upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a buy rating in a research report sent to investors on Friday morning, Zacks.com reports. The firm currently has $2.50 price objective on the biopharmaceutical companys stock. According to Zacks, Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for []
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Friday, 03'rd Dec 2021 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
-$0.48 Earnings Per Share Expected for Assembly Biosciences, Inc. (NASDAQ:ASMB) This Quarter
06:14am, Wednesday, 01'st Dec 2021 Transcript Daily
Brokerages expect Assembly Biosciences, Inc. (NASDAQ:ASMB) to announce earnings of ($0.48) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Assembly Biosciences earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.57). Assembly Biosciences reported earnings of ($1.11) per share in the same quarter last year, which []
Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Rating of Hold by Analysts
10:38am, Tuesday, 30'th Nov 2021 Transcript Daily
Assembly Biosciences, Inc. (NASDAQ:ASMB) has earned a consensus recommendation of Hold from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have []
Renaissance Technologies LLC Sells 221,494 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB)
09:32am, Thursday, 18'th Nov 2021 Dakota Financial News
Renaissance Technologies LLC lowered its stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) by 38.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 355,841 shares of the biopharmaceutical companys stock after selling 221,494 shares during the period. Renaissance Technologies LLC owned 0.79% []
MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered
Assembly Bio Announces October Conference Participation
08:00am, Wednesday, 06'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:04pm, Friday, 01'st Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
ASMB Stock: Over 15% Decrease Pre-Market Explanation
07:51am, Thursday, 02'nd Sep 2021
The stock price of Assembly Biosciences, Inc. (Nasdaq: ASMB) fell by over 15% pre-market. This is why it happened.